Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.
Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.
复制标题
DOI：
10.1016/j.biopha.2021.112276
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Vines CM
中科院分区：
文献类型：
--
作者：
Malek RJ;Bill CA;Vines CM
能够逃避疫苗产生的免疫反应的SARS-CoV-2变体的潜在出现对疫苗接种工作构成了迫在眉睫的威胁，并可能延长COVID-19大流行的持续时间。此外，β冠状病毒在动物中的流行以及它们在人类中传播的先例表明，它们对未来的流行病构成持续威胁。目前，只有一种治疗药物被美国食品和药物管理局（FDA）批准用于治疗COVID-19，即瑞德西韦，尽管由于这种流行病是一种公共卫生紧急情况，其他治疗药物被授权用于紧急使用。在这篇综述中，讨论了24种不同的治疗方法，讨论了它们对COVID-19和任何潜在的未来冠状病毒相关疾病的用途。评估了它们的传统用途、抗COVID-19的作用机制以及在临床试验中的疗效。在临床试验中，评估的六种治疗方法显示出显著降低死亡率，十种治疗方法显示出某种形式的临床疗效。
The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in treating COVID-19, remdesivir, although other therapies are authorized for emergency use due to this pandemic being a public health emergency. In this review, twenty-four different treatments are discussed regarding their use against COVID-19 and any potential future coronavirus-associated illnesses. Their traditional use, mechanism of action against COVID-19, and efficacy in clinical trials are assessed. Six treatments evaluated are shown to significantly decrease mortality in clinical trials, and ten treatments have shown some form of clinical efficacy.
登录
查看更多内容
影响因子：
4.6
作者：
Arcanjo A;Logullo J;Menezes CCB;de Souza Carvalho Giangiarulo TC;Dos Reis MC;de Castro GMM;da Silva Fontes Y;Todeschini AR;Freire-de-Lima L;Decoté-Ricardo D;Ferreira-Pereira A;Freire-de-Lima CG;Barroso SPC;Takiya C;Conceição-Silva F;Savino W;Morrot A
通讯作者：
Morrot A
影响因子：
3.7
作者：
Bughani U;Saha A;Kuriakose A;Nair R;Sadashivarao RB;Venkataraman R;Patel S;Deshchougule AT;S SK;Montero E;Pai HV;Palanivelu DV;Melarkode R;Nair P
通讯作者：
Nair P
影响因子：
--
作者：
Clinckemalie, Liesbeth;Spans, Lien;Claessens, Frank
通讯作者：
Claessens, Frank
影响因子：
158.5
作者：
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者：
Hullsiek, Kathy H.
影响因子：
4.3
作者：
BAIRD, RJ
通讯作者：
BAIRD, RJ